Aderbasib

Aderbasib

Aderbasib (previously codenamed INCB7839) is a pharmaceutical compound known as a sheddase inhibitor, speculated to hinder tumor cell proliferation. Aderbasib is unique due to its action on a broad spectrum of receptor classes and subclasses. One of its primary mechanisms is believed to involve the modulation of the tumor necrosis factor within cancer cells. The compound was under research and development by Incyte, targeting its potential use as an adjunctive therapy for metastatic breast cancer. However, the developmental trajectory was terminated in 2011, following inconsistencies in research findings after the initial promise shown in Phase II trials.

Pharmacology

Mechanism of Action

Aderbasib exerts its anti-tumoral effects through the inhibition of sheddase enzymes. By acting on multiple receptor categories, aderbasib primarily targets the regulation of tumor necrosis factors within cancerous cells, a process crucial for cell proliferation and tumor growth.

Medical Uses

Although aderbasib demonstrated significant promise in early-phase clinical trials, its primary intended use was as an adjunct therapy for patients with metastatic breast cancer. The aim was to enhance the efficacy of standard treatments and potentially curb the progression of the disease.

Clinical Development

Aderbasib's journey through clinical trials was marked by initial optimism followed by abrupt termination:

• Early-stage (Phase I and II) clinical trials showcased positive outcomes, suggesting its potential efficacy in treating metastatic breast cancer.
• Contradictory results emerged in subsequent investigations, raising concerns about the drug's consistent effectiveness and its long-term safety profile.
• In light of these inconsistencies, Incyte opted to halt the development of aderbasib in 2011.

Side Effects

While the complete safety profile of aderbasib was not fully elucidated due to its halted development, common side effects observed in clinical trials included:

• Fatigue
• Nausea
• Diarrhea
• Gastrointestinal disturbances

Future Implications

While the development of aderbasib as a treatment for metastatic breast cancer was discontinued, the research provided valuable insights into the role of sheddase inhibitors in oncology. It is plausible that future compounds might build upon the foundational knowledge gleaned from aderbasib's research.

See also

• Tumor Necrosis Factor
• Oncology
• Metastatic breast cancer
• Clinical trials
• Pharmacology

External links

• NCI Thesaurus